The effect of selective serotonin reuptake inhibitor (SSRI) treatment on mean platelet volume in major depressive disorder (MDD) patients

Basit Öğe Kaydı
dc.contributor.authorDemircan, Fatih
dc.contributor.authorGözel, Nevzat
dc.contributor.authorKılınç, Faruk
dc.contributor.authorYılmaz, Musa
dc.contributor.authorDönder, Emir
dc.contributor.authorAtmaca, Murad
dc.date.accessioned2024-04-24T17:56:51Z
dc.date.available2024-04-24T17:56:51Z
dc.date.issued2016
dc.departmentDicle Üniversitesien_US
dc.description.abstractIntroduction: Patients with depression are at an increased risk for cardiovascular disease. Mean platelet volume (MPV) provides a measurement of activated platelets; increasing platelet activation is one of the mechanisms that may link depression and ischemic cardiac disease. Material and method: 100 newly diagnosed patients with major depressive disorder (MDD) and 100 healthy controls admitted to our outpatient clinics. We started selective serotonin reuptake inhibitor (SSRI) treatment in the MDD patients and followed them for 3 months. Patients' laboratory tests and physical, neurological, and psychiatric examinations were performed both at diagnosis and after 3 months of treatment. Results: The MDD group consisted of 90 people and the control group consisted of 88 people met the inclusion/exclusion criteria. There was no significant difference between the ages of the groups (p = 0.28). There were more males within the MDD group (55.6%). MPV was significantly greater in MDD group (p < 0.001); MPV levels showed significantly decline after treatment with SSRIs (p < 0.001). The platelet counts were also significantly low in MDD patients when compared with the control group, with the difference being statistically significant (p < 0.001). No significant difference was observed in platelet counts after treatment. Severity of depression also declined after treatment. The average Montgomery-Asberg Depression Rating Scale (MADRS) score decreased 9.23 points; the difference was statistically significant (p < 0.001). Conclusion: We conclude that MPV can be an indicator of platelet activity in patients with MDD and SSRIs can be used along with MPV to help identifying and treating coronary artery disease in MDD patients. According to our findings, SSRIs may have an antiplatelet action in addition to their antidepressant effects, which may be beneficial for MDD patients with coronary artery disease.en_US
dc.identifier.citationDemircan, F., Gözel, N., Kılınç, F., Yılmaz, M., Dönder, E. ve Atmaca, M. (2016). The effect of selective serotonin reuptake inhibitor (SSRI) treatment on mean platelet volume in major depressive disorder (MDD) patients. Acta Medica Mediterranea, 32(1), 93-96.
dc.identifier.doi10.19193/0393-6384_2016_1_14
dc.identifier.endpage96en_US
dc.identifier.issn0393-6384
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-84969150887
dc.identifier.scopusqualityN/A
dc.identifier.startpage93en_US
dc.identifier.urihttps://doi.org/10.19193/0393-6384_2016_1_14
dc.identifier.urihttps://hdl.handle.net/11468/23690
dc.identifier.volume32en_US
dc.identifier.wosWoSIDEksik
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoenen_US
dc.publisherA. CARBONE Editoreen_US
dc.relation.ispartofActa Medica Mediterranea
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCoronary artery diseaseen_US
dc.subjectDepressionen_US
dc.subjectMean platelet volumeen_US
dc.subjectSsrıen_US
dc.titleThe effect of selective serotonin reuptake inhibitor (SSRI) treatment on mean platelet volume in major depressive disorder (MDD) patientsen_US
dc.titleThe effect of selective serotonin reuptake inhibitor (SSRI) treatment on mean platelet volume in major depressive disorder (MDD) patients
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu